| Cat. No. | Product Name | Field of Application | Chemical Structure |
|---|---|---|---|
| A311 | NGM313 Featured |
|
|
| A312 | RG7992 Featured |
|
|
| A313 | Fianlimab Featured | Fianlimab (REGN3767) is a human monoclonal antibody that targets the immune checkpoint receptor LAG-3 on T cells and has anti-tumour activity. |
|
| A314 | Favezelimab Featured | Favezelimab (MK-4280) is a humanized anti-LAG-3 monoclonal antibody that blocks the interaction between LAG-3 and its ligand MHC class II. Favezelimab has the potential for colorectal cancer (CRC) research combined with the PD-L1 inhibitor Pembrolizumab (HY-P9902). |
|
| A315 | Ieramilimab Featured | Ieramilimab (LAG525; IMP701) is a humanized IgG4 monoclonal antibody that binds to LAG-3, resulting in inhibition of LAG-3 interaction with MHC-II molecules. |
|
| A316 | Encelimab Featured | Encelimab is an anti-LAG3 antibody. Encelimab blocks the interaction between LAG-3 and MHC II, and enhances T-cell activation. Encelimab alone or in combination with an anti-PD-1 antibody reduces tumor size in a lymphoma mice model (A20 cell xenograft). |
|
| A317 | Relatlimab Featured | Relatlimab (BMS-986016) is a human monoclonal antibody anti-LAG-3 antibody generated by immunization of transgenic mice bearing human immunoglobulin miniloci with recombinant LAG-3 protein. Relatlimab blocks LAG-3/MHC II interaction with an IC50 value of 0.67 nM and LAG-3/FGL1 interaction with an IC50 value of 0.019 nM. Relatlimab can be used in research of cancer. |
|
| A318 | Miptenalimab Featured | Miptenalimab (BI-754111) is an anti-human LAG-3 antibody (KD: 88.6 nM for h LAG-3). Miptenalimab blocks the interaction of LAG-3 with its ligand MHC-II. |
|
| A319 | SAR428926 Featured |
|
|
| A320 | Brigham and Womens anti-LAP Featured |
|
|
| A321 | Mibavademab Featured |
|
|
| A322 | MB-311 Featured |
|
|
| A323 | Anti-LIF Antibody (MSC-1) Featured |
|
|
| DC66946 | Patulin Featured | Patulin (Terinin) is a mycotoxin produced by fungi including the Aspergillus, Penicillium, and Byssochlamys species, causes chromosome breakage, mutation, teratogenic and cytotoxic. Patulin induces autophagy-dependent apoptosis through lysosomal-mitochondrial axis, and causes DNA damage. |
|
| A324 | Polzastobart Featured | Polzastobart (JTX-8064) is a humanized IgG4 monoclonal antagonist antibody that selectively binds LILRB2 and prevents it from binding its ligands, classical and non-classical MHC I molecules. Polzastobart enhances pro-inflammatory cytokine production in macrophages by blocking the ability of LILRB2 to bind HLA-A/B and/or HLA-G, a marker of immunotolerance on cancer cells. Polzastobart is a macrophage immune checkpoint inhibitor. |
|
| A325 | Merck patent anti-ILT3 complex Featured |
|
|
| A326 | U.Texas patent anti-LILRB4 Featured |
|
|
| A327 | Opicinumab Featured | Opicinumab (BIIB033) is a monoclonal antibody against LINGO-1 and has potential application in acute optic neuritis and relapse multiple sclerosis. |
|
| A328 | Ladiratuzumab Featured | Ladiratuzumab (hLIV22) is an anti-LIV-1/ZIP6 humanized monoclonal antibody. Ladiratuzumab, conjugated with the microtubule disrupting agent, MMAE (HY-15162) to compose SGN-LIV1A, an antibody-drug conjugate (ADC). Ladiratuzumab can be used for research of breast cancer. |
|
| DC66951 | Aflatoxin M2 Featured | Aflatoxin M2 is a major metabolite of Aflatoxin B1. Aflatoxin M2 is a mycotoxin produced by the fungi Aspergillus flavus and Aspergillus parasiticus. The level of toxicity associated with Aflatoxin is Aflatoxin B1>Aflatoxin M1>Aflatoxin G1>Aflatoxin B2>Aflatoxin M2>Aflatoxin G2. |
|
| A329 | Simtuzumab Featured | Simtuzumab (AB 0024; GS 6624) is a monoclonal antibody directed against Lysyl oxidase like-2 (LOXL2). Simtuzumab can be used for the research of primary sclerosing cholangitis (PSC). |
|
| A330 | RG7841 Featured |
|
|
| A331 | Anti-LY75/CD205 Antibody (MEN1309) Featured |
|
|
| A332 | CDX-1401 Featured |
|
|
| A333 | Ontamalimab Featured | Ontamalimab (SHP647) is a fully-human IgG2 monoclonal antibody targeting mucosal addressin cell adhesion molecule-1 (MAdCAM-1). Ontamalimab can be used for the research of Crohn's disease. |
|
| A334 | CT Atlantic patent anti-MAGE-A3 Featured |
|
|
| A335 | IMC-C103C Featured |
|
|
| A336 | Narsoplimab Featured | Narsoplimab (OMS 721) is a high-affinity fully human immunoglobulin gamma 4 (IgG4) monoclonal antibody that binds MASP-2 and blocks lectin pathway activation. Narsoplimab can be used in research of hematopoietic stem-cell transplantation and SARS-CoV-2. |
|
| A337 | Oxford Bio patent anti-Matriptase Featured |
|
|
| A338 | Tokai U. Patent Anti-Meflin Featured |
|
